Dextran sulfate acts as an endothelial cell protectant and inhibits human complement and natural killer cell-mediated cytotoxicity against porcine cells

Thomas Laumonier, Alexander J. Walpen, Christine Maurus, Paul Mohaçsi, Katja Matozan, Elena Korchagina, Nicolai V. Bovin, Bernard Vanhove, Jörg D. Seebach, Robert Rieben

Transplantation · 2003 · 65 citations · 25 references

Abstract

DXS binds to porcine cells and protects them from complement- and NK cell-mediated injury in vitro. It might therefore be used as a novel therapeutic strategy to prevent xenograft rejection and has potential for clinical application as an "EC protectant."

References

25